Clinical Trial Update: Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality [Phase 2]

View source ↗

Summary

Phase 2 trial assessing lenalidomide safety and efficacy in myelodysplastic syndromes with deletion 5q cytogenetic abnormality has completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: Celgene | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2010-06-09